Finerenone Dose–Exposure–Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria

BACKGROUND: Finerenone is a nonsteroidal selective mineralocorticoid receptor antagonist (MRA) that demonstrated efficacy in delaying the progression of chronic kidney disease (CKD) and reducing cardiovascular events in patients with CKD and type 2 diabetes mellitus in FIDELIO-DKD, where 5734 patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Goulooze, Sebastiaan Camiel, Snelder, Nelleke, Seelmann, Andreas, Horvat-Broecker, Andrea, Brinker, Meike, Joseph, Amer, Garmann, Dirk, Lippert, Joerg, Eissing, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891103/
https://www.ncbi.nlm.nih.gov/pubmed/34786651
http://dx.doi.org/10.1007/s40262-021-01083-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891103/
https://www.ncbi.nlm.nih.gov/pubmed/34786651
http://dx.doi.org/10.1007/s40262-021-01083-1

Ejemplares similares